

Atreya Dash

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10936381/publications.pdf>

Version: 2024-02-01

60
papers

3,275
citations

218677

26
h-index

155660

55
g-index

61
all docs

61
docs citations

61
times ranked

4087
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2022, 128, 269-274.	4.1	3
2	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. <i>Journal of Urology</i> , 2022, 207, 805-813.	0.4	3
3	Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence. <i>JAMA Network Open</i> , 2022, 5, e2148329.	5.9	12
4	Clinical impact of PSMA PET in patients with biochemically recurrent prostate cancer after locoregional definitive therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17009-e17009.	1.6	2
5	Evaluation of physical function and its association with body composition, quality of life and biomarkers in cancer cachexia patients. <i>Clinical Nutrition</i> , 2021, 40, 978-986.	5.0	16
6	Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. <i>Urology</i> , 2021, 149, 154-160.	1.0	4
7	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. <i>Urology Practice</i> , 2021, 8, 576-582.	0.5	1
8	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020, 6, e203187.	7.1	30
9	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 1549-1557.	1.6	48
10	Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. <i>Journal of Urology</i> , 2020, 203, 522-529.	0.4	75
11	Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy. <i>Journal of Urology</i> , 2020, 204, 450-459.	0.4	26
12	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 438-445.	3.9	22
13	Continued 5 α -Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. <i>Journal of Urology</i> , 2019, 201, 106-112.	0.4	4
14	Does the Diagnosis of Bladder Cancer Lead to Higher Rates of Smoking Cessation? Findings from the Medicare Health Outcomes Survey. <i>Journal of Urology</i> , 2019, 202, 241-246.	0.4	13
15	Increasing use of neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC): Prognostic impact of non-standard of care (SOC) regimens.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4532-4532.	1.6	1
16	Neoadjuvant chemotherapy utilization in muscle-invasive bladder cancer: Increasing yet inappropriate use?. <i>Journal of Clinical Oncology</i> , 2019, 37, 441-441.	1.6	0
17	Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 262-262.	1.6	0
18	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2018, 73, 706-712.	1.9	17

#	ARTICLE	IF	CITATIONS
19	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. <i>European Urology</i> , 2018, 74, 211-217.	1.9	30
20	Disparities in Access and Regionalization of Care in Testicular Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e785-e793.	1.9	32
21	Health Related Quality of Life Following Radical Cystectomy: Comparative Analysis from the Medicare Health Outcomes Survey. <i>Journal of Urology</i> , 2018, 199, 669-675.	0.4	27
22	The impact of readmission hospital on failure-to-rescue rates following major urologic cancer surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 156.e1-156.e7.	1.6	2
23	Patency and Incontinence Rates After Robotic Bladder Neck Reconstruction for Vesicourethral Anastomotic Stenosis and Recalcitrant Bladder Neck Contractures: The Trauma and Urologic Reconstructive Network of Surgeons Experience. <i>Urology</i> , 2018, 118, 227-233.	1.0	56
24	Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2018, 391, 2525-2536.	13.7	537
25	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2017, 72, 448-454.	1.9	61
26	Patient-centered risk stratification of disposition outcomes following radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 235.e17-235.e23.	1.6	22
27	Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients. <i>Urology</i> , 2016, 91, 70-76.	1.0	16
28	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. <i>Journal of Urology</i> , 2016, 195, 313-320.	0.4	122
29	Primary Desmoplastic Melanoma of the Penis. <i>Case Reports in Urology</i> , 2015, 2015, 1-3.	0.3	2
30	The <sc>RAZOR</sc> (randomized open vs robotic cystectomy) trial: study design and trial update. <i>BJU International</i> , 2015, 115, 198-205.	2.5	73
31	An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 73-78.	0.4	35
32	The Role of Postchemotherapy Surgery in Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2015, 42, 331-342.	1.8	12
33	A novel tool to predict outcomes following radical cystectomy using age and co-morbidity status.. <i>Journal of Clinical Oncology</i> , 2015, 33, 354-354.	1.6	0
34	Spontaneous Regression of Crizotinib-Associated Complex Renal Cysts During Continuous Crizotinib Treatment. <i>Oncologist</i> , 2014, 19, 1008-1010.	3.7	32
35	Weighted Versus Unweighted Charlson Score to Predict Long-term Other-cause Mortality in Men with Early-stage Prostate Cancer. <i>European Urology</i> , 2014, 66, 1002-1009.	1.9	21
36	Fluoroquinolone Resistant Rectal Colonization Predicts Risk of Infectious Complications after Transrectal Prostate Biopsy. <i>Journal of Urology</i> , 2014, 192, 1673-1678.	0.4	65

#	ARTICLE	IF	CITATIONS
37	Consideration of comorbidity in risk stratification prior to prostate biopsy. <i>Cancer</i> , 2013, 119, 2413-2418.	4.1	5
38	Screening Rectal Culture to Identify Fluoroquinolone-resistant Organisms Before Transrectal Prostate Biopsy: Do the Culture Results Between Office Visit and Biopsy Correlate?. <i>Urology</i> , 2013, 82, 67-73.	1.0	24
39	Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer. <i>Cancer</i> , 2013, 119, 3446-3453.	4.1	10
40	TGF- β 2 mediated DNA methylation in prostate cancer. <i>Translational Andrology and Urology</i> , 2012, 1, 78-88.	1.4	18
41	Use of total illness burden index for prostate cancer (TIBI-CaP) to predict nonprostate cancer morbidity.. <i>Journal of Clinical Oncology</i> , 2012, 30, 215-215.	1.6	0
42	Prevalence and Significance of Fluoroquinolone Resistant Escherichia coli in Patients Undergoing Transrectal Ultrasound Guided Prostate Needle Biopsy. <i>Journal of Urology</i> , 2011, 185, 1283-1288.	0.4	164
43	Improved Prediction of Long-Term, Other Cause Mortality in Men With Prostate Cancer. <i>Journal of Urology</i> , 2011, 186, 1868-1873.	0.4	24
44	Overtreatment of men with low-risk prostate cancer and significant comorbidity. <i>Cancer</i> , 2011, 117, 2058-2066.	4.1	122
45	Comorbidity and competing risks for mortality in men with prostate cancer. <i>Cancer</i> , 2011, 117, 4642-4650.	4.1	86
46	Copy number and gene expression differences between African American and Caucasian American prostate cancer. <i>Journal of Translational Medicine</i> , 2010, 8, 70.	4.4	50
47	Pelvic lymph node dissection and outcome of robot-assisted radical cystectomy for bladder carcinoma. <i>Journal of Robotic Surgery</i> , 2009, 3, 7-12.	1.8	11
48	The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. <i>Cancer</i> , 2008, 112, 800-805.	4.1	22
49	A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder. <i>Cancer</i> , 2008, 113, 2471-2477.	4.1	239
50	Impact of Socioeconomic Factors on Prostate Cancer Outcomes in Black Patients Treated with Surgery. <i>Urology</i> , 2008, 72, 641-646.	1.0	14
51	Failure of Percutaneous Endoscopic Resection of a Renal Cystic Nephroma on Longer-Term Follow-Up. <i>Journal of Endourology</i> , 2008, 22, 1505-1508.	2.1	3
52	Integrative Analysis of Genomic Aberrations Associated with Prostate Cancer Progression. <i>Cancer Research</i> , 2007, 67, 8229-8239.	0.9	103
53	Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. <i>BJU International</i> , 2006, 97, 939-945.	2.5	222
54	Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. <i>Cancer</i> , 2006, 107, 506-513.	4.1	360

#	ARTICLE	IF	CITATIONS
55	Percutaneous Treatment of Renal Cystic Nephroma. Journal of Endourology, 2005, 19, 724-725.	2.1	3
56	Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB Journal, 2005, 19, 1-23.	0.5	88
57	Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling. Urology, 2004, 64, 117-122.	1.0	33
58	Changes in Differential Gene Expression because of Warm Ischemia Time of Radical Prostatectomy Specimens. American Journal of Pathology, 2002, 161, 1743-1748.	3.8	138
59	Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. Urology, 2002, 60, 276-280.	1.0	38
60	Ureteroscopic treatment of renal calculi in morbidly obese patients: a stone-matched comparison. Urology, 2002, 60, 393-397.	1.0	76